Certain Financial Statement Caption Information (Tables)

6 Months Ended

Jun. 30, 2024

Certain Financial Statement Caption Information [Abstract]

Schedule of Company's Short-Term Investments

The following table summarizes the Company’s short-term investments (in thousands):

	Maturity	Amortized		Unrealized		Unrealized			Estimated
	(in years)	Cost		Gains		Losses			Fair Value
June 30, 2024
U.S. treasury securities	1 or less	$	22,252		-	$	(10	)	$	22,242
Total		$	22,252	$	-	$	(10	)	$	22,242
December 31, 2023
U.S. treasury securities	1 or less	$	17,632		18		-		$	17,650
Total		$	17,632	$	18	$	-		$	17,650

Schedule of Accrued Expenses

Accrued expenses consisted of the following (in thousands):

	June 30,		December 31,
	2024		2023
Accrued payroll and other employee benefits	$	1,991	$	3,054
Clinical development		3,436		1,850
Biocon and its subsidiaries chemistry, manufacturing and controls services - related party		363		719
Biocon clinical development related to ulcerative colitis study - related party		272		415
Non-clinical research		441		228
Other accruals		400		431
Total accrued expenses	$	6,903	$	6,697